LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651 - Annals of Oncology

Despite recent tx advances in R/M SCCHN, durable survival benefit remains an elusive goal. CheckMate 651 (NCT02741570), a phase 3 randomized trial, evaluated N+I vs EXTREME regimen as 1L tx for platinum-eligible R/M SCCHN.